CN110755420B - 铁死亡抑制剂Ferrostatin-1及其衍生物在制备药物中的应用 - Google Patents
铁死亡抑制剂Ferrostatin-1及其衍生物在制备药物中的应用 Download PDFInfo
- Publication number
- CN110755420B CN110755420B CN201910950367.2A CN201910950367A CN110755420B CN 110755420 B CN110755420 B CN 110755420B CN 201910950367 A CN201910950367 A CN 201910950367A CN 110755420 B CN110755420 B CN 110755420B
- Authority
- CN
- China
- Prior art keywords
- ferrostatin
- mice
- bone marrow
- derivatives
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 13
- 230000034994 death Effects 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 8
- UJHBVMHOBZBWMX-UHFFFAOYSA-N ferrostatin-1 Chemical compound NC1=CC(C(=O)OCC)=CC=C1NC1CCCCC1 UJHBVMHOBZBWMX-UHFFFAOYSA-N 0.000 title abstract description 65
- 229940079593 drug Drugs 0.000 title abstract description 17
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 230000005855 radiation Effects 0.000 claims abstract description 15
- 230000001154 acute effect Effects 0.000 claims abstract description 13
- 206010033661 Pancytopenia Diseases 0.000 claims abstract description 12
- 208000024389 cytopenia Diseases 0.000 claims abstract description 11
- 238000001959 radiotherapy Methods 0.000 claims abstract description 11
- 241000699670 Mus sp. Species 0.000 abstract description 53
- 230000004083 survival effect Effects 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 19
- 210000000952 spleen Anatomy 0.000 abstract description 17
- 210000004698 lymphocyte Anatomy 0.000 abstract description 15
- 210000000265 leukocyte Anatomy 0.000 abstract description 13
- 210000004027 cell Anatomy 0.000 abstract description 8
- 210000000683 abdominal cavity Anatomy 0.000 abstract description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract description 6
- 231100000636 lethal dose Toxicity 0.000 abstract description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 239000007928 intraperitoneal injection Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000001395 Acute radiation syndrome Diseases 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 206010068142 Radiation sickness syndrome Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000005025 nuclear technology Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
Abstract
本发明公开了铁死亡抑制剂Ferrostation‑1及其衍生物在制备药物中的应用，属于医药技术领域，提供了Ferrostation‑1及其衍生物在制备治疗骨髓型急性放射病和放疗诱导血细胞降低症药物中的应用的新用途。采用Ferrostatin‑1腹腔注射致死剂量辐照的小鼠可使辐照小鼠存活率提高到60%（150天），外周血白细胞数量明显升高；骨髓粒‑巨系造血祖细胞数量明显恢复；骨髓有核细胞明显恢复（HE切片）；脾脏淋巴细胞存活率明显恢复；脾脏淋巴细胞数量明显回升（HE切片），Ferrostation‑1及其衍生物对治疗骨髓型急性放射病和放疗诱导血细胞降低症具有很好的效果。
Description
技术领域 本发明属于医药技术领域，尤其涉及铁死亡抑制剂Ferrostatin-1及其衍生物在制备药物中的应用。
背景技术 核技术在军事和能源领域的广泛应用极大推动了人类社会的发展，但这些核技术的应用也给人类社会的生存带来严重的威胁。根据可查询记录，至今全世界范围内至少发生1054起核试验，2起原子弹爆炸，7起潜艇核反应堆事故，100余起核电事故。核武器/辐射事故所致的人体电离辐射暴露最常见的后果是骨髓型急性放射病的发生。骨髓型急性放射病是电离辐射急性暴露诱导的以骨髓组织损伤为主的全身性辐射损伤，它是在造血组织抑制和破坏的基础上，全血细胞减少，主要表现为出血、感染，严重者可导致死亡。骨髓型急性放射病根据受照剂量的不同分为轻度（1-2 Gy）、中度（2-4 Gy）、重度（4-6 Gy）和极重度（6-10 Gy）四种类型。在目前医疗技术水平下，需要干预且可以干预的是中度到极重度骨髓型急性放射病。中度以上的骨髓型急性放射病发生机制为辐照损伤骨髓造血干细胞后，导致外周血血细胞数量下降，引发出血和感染等症状，已有的研究结果证明骨髓型急性放射病的骨髓造血干细胞以及脾脏淋巴细胞存在铁死亡。
目前针对骨髓型急性放射病和放疗诱导血细胞降低症还没有非常有效的药物，临床上主要使用粒细胞集落刺激因子（G-CSF，非格司亭）、聚乙二醇粒细胞集落刺激因子（沙莫司亭）和安多霖胶囊等药物进行辅助治疗以恢复骨髓造血干细胞的造血功能，但这些药并不能够完全阻止疾病进展和治愈疾病，因此开发更加高效的骨髓型急性放射病和放疗诱导血细胞降低症的治疗药物非常重要。
Ferrostation-1是基于抑制脂质过氧化的铁死亡抑制剂，现有报道提示Ferrostatin-1可通过阻断胱氨酸转运和谷胱甘肽产生而抑制铁依赖的癌细胞死亡，其结构式为：
至今为止，还没有Ferrostation-1用于制备治疗骨髓型急性放射病和放疗诱导血细胞降低症药物的相关报道。
发明内容
本发明提供了铁死亡抑制剂Ferrostation-1及其衍生物在制备药物中的应用，目的在于提供Ferrostation-1及其衍生物在制备治疗骨髓型急性放射病和放疗诱导血细胞降低症药物中的应用这一新用途。
为更好的理解本发明实质，下面将利用Ferrostation-1及其衍生物的药理实验及结果来说明其在制备治疗骨髓型急性放射病和放疗诱导血细胞降低症药物中的应用。
首先采用Ferrostatin-1腹腔注射致死剂量辐照的小鼠，观察辐照小鼠的存活率，从动物整体水平确认Ferrostatin-1治疗骨髓型急性放射病和放疗诱导血细胞降低症作用；
然后分别观察Ferrostatin-1作用的辐照小鼠外周血白细胞、粒-巨系造血祖细胞数量的改变，确认Ferrostatin-1对于辐照小鼠骨髓粒-巨系造血祖细胞数量的恢复作用，此结果经骨髓HE切片进一步确认；
最后观察Ferrostatin-1作用的辐照小鼠脾脏淋巴细胞存活率的改变，确认Ferrostatin-1对于辐照小鼠脾脏淋巴细胞存活率的恢复作用，此结果经脾脏HE切片进一步确认。
有益效果：本发明提供了铁死亡抑制剂Ferrostation-1及其衍生物在制备药物中的应用，目的在于提供Ferrostation-1及其衍生物在制备治疗骨髓型急性放射病和放疗诱导血细胞降低症药物中的应用这一新用途。Ferrostation-1作为一种铁死亡抑制剂能阻断铁介导的脂质过氧化过程，达到抑制细胞铁死亡发生的目的。采用Ferrostatin-1腹腔注射致死剂量辐照的小鼠可使辐照小鼠存活率提高到60% （150天），外周血白细胞数量明显升高；骨髓粒-巨系造血祖细胞数量明显恢复；骨髓有核细胞明显恢复（HE切片）；脾脏淋巴细胞存活率明显恢复；脾脏淋巴细胞数量明显回升（HE切片），Ferrostation-1及其衍生物对治疗骨髓型急性放射病和放疗诱导血细胞降低症具有很好的效果。
附图说明
图1为本发明实施例中Ferrostatin-1对gamma射线辐照小鼠生存率的影响示意图，图中Fer为Ferrostatin-1；
图2为本发明实施例中Ferrostation-1对辐照小鼠（15和30天）外周血白细胞数量的影响示意图，图中Fer-1 为Ferrostatin-1；
图3为本发明实施例中Ferrostation-1对辐照小鼠（120天）外周血白细胞数量的影响示意图，图中Fer-1 为Ferrostatin-1；
图4为本发明实施例中Ferrostation-1对辐照小鼠骨髓粒-巨系造血祖细胞数量的影响示意图，A为粒-巨系造血祖细胞集落图，B为粒-巨系造血祖细胞集落数据统计图，图中Fer-1 为Ferrostatin-1；
图5为本发明实施例中Ferrostation-1作用的辐照小鼠（120天）股骨骨髓HE切片(× 20)图，图中Fer-1 为Ferrostatin-1；
图6为本发明实施例中Ferrostation-1对辐照小鼠（1天）脾脏淋巴细胞存活率的影响示意图，图中Fer为Ferrostatin-1；
图7为本发明实施例中Ferrostation-1作用的辐照小鼠（120天）脾脏HE切片(×20)图，图中Fer-1 为Ferrostatin-1。
具体实施方式
下面结合附图和具体实施例对本发明进行详细说明：
本实施例采用的Ferrostation-1购买于APExBIO公司（CAS号：347174-05-4）。
1、Ferrostatin-1对于致死剂量辐照小鼠存活率的影响
ICR小鼠分为四组：0Gy组、0Gy + Ferrostatin-1组、10Gy组、10Gy +Ferrostatin-1组，每组10只；0Gy组和10Gy组包含溶剂对照； Co60γ射线辐照小鼠，辐照后第3天腹腔注射Ferrostatin-1(2 mg/kg，溶于0.01% DMSO)，然后观察辐照小鼠存活情况，研究Ferrostatin-1对于致死剂量辐照小鼠存活率的影响。
如图1所示，0Gy组和0Gy + Ferrostatin-1组的小鼠存活率一样都没有发生变化，说明Ferrostatin-1的毒副作用很小，通过10Gy组和10Gy + Ferrostatin-1组对比可以看出，10Gy + Ferrostatin-1组小鼠的存活时间变长，10Gy组辐照20天后小鼠的存活率已经为0，10Gy + Ferrostatin-1组的小鼠在150天后存活率还有60%，所以Ferrostatin-1能明显提高辐照小鼠的存活时间和存活率。
2、Ferrostatin-1对于不同剂量辐照小鼠外周血白细胞数量的影响
ICR小鼠分为0Gy组、0Gy + Ferrostatin-1组、辐照组、辐照 + Ferrostatin-1组，每组6只；0Gy组和辐照组包含溶剂对照； Co60γ射线辐照小鼠，辐照后第3天腹腔注射Ferrostatin-1(2 mg/kg，溶于0.01% DMSO)，分别于腹腔注射药物后15天、30天和120天观察小鼠外周血白细胞数量，研究Ferrostatin-1对于辐照小鼠外周血白细胞数量的影响。
如图2所示，腹腔注射药物15天、30天后观察小鼠外周血白细胞数量，从图中可以看出腹腔注射药物后15天、30天后辐照小鼠外周血白细胞数量明显提升。
如图3所示，腹腔注射药物120天后观察小鼠外周血白细胞数量，从图中可以看出腹腔注射药物后120天后辐照小鼠外周血白细胞数量明显提升，接近未辐照小鼠外周血白细胞数量。
3、 Ferrostatin-1对于辐照小鼠骨髓粒-巨系造血祖细胞数量的影响
ICR小鼠分为四组：0Gy组、0Gy + Ferrostatin-1组、4Gy组、4Gy + Ferrostatin-1组，每组6只；0Gy组和4Gy组包含溶剂对照；Co60γ射线辐照小鼠，辐照后第3天腹腔注射Ferrostatin-1(2 mg/kg，溶于0.01% DMSO)，腹腔注射后24小时取小鼠左侧股骨，制备骨髓组织细胞悬液，淋巴细胞分离液分离骨髓有核细胞，将分离出来的细胞接种在含有粒细胞集落刺激因子（10 ng/ml）的甲基纤维素培养基中培养14天后，倒置显微镜观察细胞集落数量，研究Ferrostatin-1对于辐照小鼠骨髓粒-巨系造血祖细胞数量的影响。
如图4所示，A图为粒-巨系造血祖细胞集落，圈中为集落，1个集落细胞数大于等于30个细胞；B图为粒-巨系造血祖细胞集落数据统计，通过4Gy组和4Gy + Ferrostatin-1组对比可知，腹腔注射Ferrostatin-1后辐照小鼠的骨髓粒-巨系造血祖细胞数量明显恢复。
4、 Ferrostatin-1对于辐照小鼠骨髓组织形态学的作用
ICR小鼠分为三组：0Gy组、0Gy + Ferrostatin-1组、10Gy + Ferrostatin-1组；0Gy组包含溶剂对照；Co60γ射线辐照小鼠，辐照后第3天腹腔注射Ferrostatin-1(2 mg/kg，溶于0.01% DMSO)；药物腹腔注射120天后取小鼠骨髓制作HE染色切片，观察小鼠骨髓组织形态学变化，研究Ferrostatin-1对于辐照小鼠骨髓组织的作用。如图5所示，Ferrostatin-1作用辐照小鼠120天后小鼠骨髓有核细胞数量明显恢复，已经接近对照组水平。
5、Ferrostatin-1对于辐照小鼠脾脏淋巴细胞存活率的影响
ICR小鼠分为0Gy组、0Gy + Ferrostatin-1组、辐照组和辐照 + Ferrostatin-1组，每组6只；0Gy和辐照组包含溶剂对照； Co60γ射线辐照小鼠，辐照后第3天腹腔注射Ferrostatin-1(2 mg/kg，溶于0.01% DMSO)，腹腔注射后24小时取小鼠脾脏制备脾脏细胞混悬液，淋巴细胞分离液分离淋巴细胞后CCK法检测淋巴细胞存活率，研究Ferrostatin-1对于辐照小鼠脾脏淋巴细胞存活率的影响。
如图6所示，通过4Gy组和4Gy + Ferrostatin-1组、8Gy组和8Gy + Ferrostatin-1组的对比，腹腔注射Ferrostatin-1后的辐照小鼠脾脏淋巴细胞存活率明显恢复。
6、Ferrostatin-1对于辐照小鼠脾脏组织形态学的作用
雄性ICR小鼠分为三组：0Gy组、0Gy + Ferrostatin-1组、10 Gy + Ferrostatin-1组；0Gy组包含溶剂对照；Co60γ射线辐照小鼠，辐照后第3天腹腔注射Ferrostatin-1(2 mg/kg，溶于0.01% DMSO)，药物腹腔注射120天后取小鼠脾脏制作HE染色切片，观察小鼠脾脏组织形态学变化，研究Ferrostatin-1对于辐照小鼠脾脏组织的作用。如图7所示，Ferrostatin-1作用辐照小鼠120天后小鼠脾脏白髓淋巴细胞数量明显恢复，已经接近对照组水平。
以上仅是本发明的优选实施例，将有助于本领域的技术人员进一步理解本发明，但不以任何形式限制本发明。应当指出的是对本领域的普通技术人员来说，在不脱离本发明构思的前提下，做出的若干变形和改进都属于本发明的保护范围。
Claims (2)
1.铁死亡抑制剂Ferrostation-1在制备治疗骨髓型急性放射病药物中的应用。
2.铁死亡抑制剂Ferrostation-1在制备治疗放疗诱导血细胞降低症药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910950367.2A CN110755420B (zh) | 2019-10-08 | 2019-10-08 | 铁死亡抑制剂Ferrostatin-1及其衍生物在制备药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910950367.2A CN110755420B (zh) | 2019-10-08 | 2019-10-08 | 铁死亡抑制剂Ferrostatin-1及其衍生物在制备药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110755420A CN110755420A (zh) | 2020-02-07 |
| CN110755420B true CN110755420B (zh) | 2022-08-05 |
Family
ID=69331112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910950367.2A Active CN110755420B (zh) | 2019-10-08 | 2019-10-08 | 铁死亡抑制剂Ferrostatin-1及其衍生物在制备药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110755420B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111617062A (zh) * | 2020-07-06 | 2020-09-04 | 中国医学科学院放射医学研究所 | 一种Ferrostatin-1及其衍生物在制备治疗或预防电离辐射损伤药物中的应用 |
| CN113440509B (zh) * | 2021-08-06 | 2022-10-21 | 上海市第一人民医院 | Ferrostatin-1在制备抗关节假体磨损颗粒诱导假体周围骨溶解药物中的应用 |
| CN114848624A (zh) * | 2022-05-09 | 2022-08-05 | 重庆医科大学附属儿童医院 | 一种铁死亡抑制剂在制备治疗胃炎的药物中的应用 |
| CN115093356B (zh) * | 2022-06-21 | 2024-02-23 | 广东医科大学 | 一种铁死亡诱导剂的制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453173A (zh) * | 2018-11-20 | 2019-03-12 | 复旦大学附属金山医院 | 铁死亡抑制剂的用途 |
-
2019
- 2019-10-08 CN CN201910950367.2A patent/CN110755420B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453173A (zh) * | 2018-11-20 | 2019-03-12 | 复旦大学附属金山医院 | 铁死亡抑制剂的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110755420A (zh) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110755420B (zh) | 铁死亡抑制剂Ferrostatin-1及其衍生物在制备药物中的应用 | |
| Slavin et al. | Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. | |
| Congdon et al. | Humoral factor in irradiation protection: Modification of lethal irradiation injury in mice by injection of rat bone marrow | |
| CN108670969B (zh) | 一种治疗骨髓造血功能障碍的药物 | |
| Rosoff | The role of intestinal bacteria in the recovery from whole body radiation | |
| CN110664817B (zh) | 铁调素拮抗剂ldn193189及其衍生物在制备药物中的应用 | |
| Congdon et al. | The effect of transfusions of blood showing extreme leukocytosis on survival of X-irradiated mice | |
| Di Luzio | Effect of x-irradiation and choline on the reticulo-endothelial system of the rat | |
| Mewissen et al. | Late effects of gamma radiation on mice protected with cysteamine or cystamine | |
| Smith et al. | Effect of parenteral injections of particulate matter on survival of X-irradiated animals | |
| Kurishita et al. | Post-irradiation treatment with OK432 can prevent radiation-induced bone marrow death | |
| Upton et al. | Chemical protection of the mouse against leukemia induction by roentgen rays | |
| Bisht et al. | Modification of radiation induced damage in mouse intestine by WR-2721 | |
| CN110308284B (zh) | 放射超敏蛋白Beclin1作为机体核辐射保护的靶点 | |
| Fahl et al. | Significant Reduction of Total-Body Irradiation-Induced Death in Mice Treated with PrC-210 24 Hours Postirradiation | |
| Shevchuk et al. | Adsorptive treatment of acute radiation sickness: past achievements and new prospects | |
| Yamamoto et al. | Morphologic change of Yoshida sarcoma cells and coelothelioma cells after exposing to the cell toxin from X-ray-irradiated animal | |
| RU2123344C1 (ru) | Средство для раннего лечения радиационных и комбинированных радиационно-термических поражений | |
| Ende et al. | Murine survival of lethal irradiation with the use of human umbilical cord blood | |
| Loutit | Protection against ionizing radiation: The “recovery factor” in spleen and bone-marrow | |
| Mori et al. | Role of the spleen in carbon-induced radioprotection | |
| Saini et al. | Radiation protection of pronormoblasts and normoblasts by 2-mercaptopropionylglycine (MPG) | |
| Cividalli et al. | Stimulation of thymic regeneration in irradiated mice with the RLP factor derived from sheep spleen | |
| Gengozian | Bone-marrow grafting attempts in marmosets after whole-body irradiation | |
| Tanaka et al. | Chemical radiation protection in man as revealed by chromosome aberrations in peripheral lymphocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |